Michael J Louie

4PUBLICATIONS
6CO-AUTHORS
Liquid biopsiesProperty law (excl. intellectual property law)Gene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Mar 25, 2026
UGN-102 for Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION Trial.

Sandip M Prasad, Dimitar Shishkov, Nikola Vladimirov Mihaylov

|Mar 24, 2026
Psychometric Validation of the QLQ-NMIBC24 in Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer.

Charles C Peyton, Rahul Dhanda, Tom Burke

|Nov 11, 2025
Patient-Reported Outcomes Following UGN-102 Treatment in Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: An Analysis of 3 Clinical Trials.

Charles C Peyton, Max Kates, Anagha Nadkarni

|Oct 24, 2024
Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION).

Sandip M Prasad, Dimitar Shishkov, Nikola Vladimirov Mihaylov

Pageof 1

Frequent Collaborators

2 joint publications

Max Kates

2 joint publications

Angela M Stover

1 joint publications

Alexandre Khuskivadze

1 joint publications

Pencho Genov